RxDoctor Payments Data

Gregory Slagle, MD

Anesthesiology · Hot Springs, ARNPI 1407842917

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 53 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Boston Scientific at 59.0% of the total.

$1,092in general payments, 2019–2025

Across 53 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$644
  • Collegium Pharmaceutical, Inc.$112
  • Medtronic$85
  • AbbVie$72
  • Amgen$57
  • Pfizer$55
  • plus $67 from 2 others

What the payments were for

  • Food & beverage$1,092100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,092 in reported general payments places this provider in the 85th percentile of 300 anesthesiology providers in Arkansas.

See all anesthesiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$580,119
Medicare patients
301
Services billed
9,406

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,118$23,171
Xtampza ErOxycodone Myristate30$22,937
Fentanyl182$20,791
Buprenorphine48$12,262
Morphine Sulfate ErMorphine Sulfate414$10,532
MovantikNaloxegol Oxalate18$7,111
ButransBuprenorphine13$7,018
Tizanidine Hcl571$6,967
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen214$5,190
Oxycodone Hcl243$4,547
Gabapentin228$3,901
Pregabalin125$2,598
Tramadol Hcl194$2,052
Cyclobenzaprine Hcl178$1,746
Diclofenac Sodium96$1,309

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$112$22,93730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 300 anesthesiology providers in Arkansas.

Other anesthesiology in Hot Springs

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →